FMCT-pc1. We are funding a preclinical study aimed at optimizing combinations of metabolic therapies to treat metastatic cancer. In general, this treatment modality, called the “press pulse” strategy, aims to “press” on the cancer cells by starving them of their preferred fuels followed by the application of oxidative stressors as a “pulse” to kill the cancer cells. Currently research is testing the inclusion of the glycolytic inhibitor 2-DG with DON (6-Diazo-5-oxo-L-norleucine), HBOT, and a restricted ketogenic diet.
FMCT-pc2. We are funding a study that aims to optimize an in vitro experimental assay that is capable of testing individual small molecules or combinations of small molecule’s effect on various epigenetic clocks. The goal of this project is to develop a system that is capable of the rapid screening of antiaging interventions. In this way, we hope to speed up the development of viable antiaging therapies. It is our strong belief that these interventions not only have potential to treat cancer once it has developed, but also as an intervention to prevent cancers from developing in the first place.
We are funding research to test the preclinical efficacy of a special formulation of mebendazole designed to make the active ingredient more bioavailable and increase the uptake within cancer cells. Mebendazole is a FDA approved medication that has a favorable safety profile.
FMCT-ct1. We are in the preliminary planning to fund a two-armed, phase 2 clinical trial testing the adjunctive efficacy of the ketogenic diet (arm-1), and a metabolic “press-pulse”, combination therapy (arm-2) on Glioblastoma multiforme. These two intervention arms will be compared to the median overall survival of historical controls in order to determine efficacy. This will be the largest and most comprehensive study of the efficacy of adjunctive metabolic therapies to date.